Incannex Healthcare (IXHL) EBT Margin (2024)
Incannex Healthcare (IXHL) posted EBT Margin of 49116.67% for Q4 2024, down 570.6% sequentially from 7324.32% in Q3 2024.
Incannex Healthcare (IXHL) EBT Margin (2024) Analysis & Trends
Incannex Healthcare has reported EBT Margin for 1 years, with the latest figure at 49116.67% in Q4 2024.
- Quarterly EBT Margin changed N/A year-over-year to 49116.67% in Q4 2024, while the trailing twelve-month figure through Jun 2025 was 54517.44% (changed N/A YoY) and the FY2025 annual result came in at 54517.44%, up 9905756.0% from the prior year.
- EBT Margin fell to 49116.67% in Q4 2024 per IXHL's latest filing, from 7324.32% in the prior quarter.
- Over five years, EBT Margin peaked at 7324.32% in Q3 2024 and troughed at 49116.67% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Incannex Healthcare | 42.23 Mn | 42.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -49,116.67% |
| Sep 30, 2024 | -7,324.32% |